Answers are grounded in this paper and cite their sources.
Liver transplantation is currently a life-saving treatment for many patients withthe failure of this organ. Both the quality and length of life after transplantationare similar to those of the general population. This is due to regular checkupsand more effective immunosuppressive treatment. Core needle biopsyremains the gold standard in diagnosing changes in the graft, mainly acuteand chronic rejection processes. Unfortunately, we are still unable to preventall phenomena that damage the liver, especially at the advanced stage.Therefore, new markers are needed to diagnose, differentiate, and predicta worse prognosis for allograft survival. The review aims to present newtissue and serological markers that can potentially help in the management ofpatients after transplantation. The role of the complement, apoptosis, immunecheckpoint inhibitors, and proteins controlling inflammation was discussed.Serological factors such as donor-derived cell-free DNA (dd-cfDNA) and bloodmiRNA were also discussed. Finally, the potential role of artificial intelligence(AI) in the histopathological diagnosis of transplanted liver was also presented.
No takes yet. Share an insight, caveat, or question.
Sylwia Szymańska (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: